The Journal of Practical Medicine ›› 2022, Vol. 38 ›› Issue (22): 2880-2884.doi: 10.3969/j.issn.1006⁃5725.2022.22.021

• Reviews • Previous Articles     Next Articles

Research progress of PDK4 and drug resistance in non⁃small cell lung cancer

WANG Xuechun*，LIANG Ail⁃ ing，LIU Yongjun.   

  1. Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics，Dongguan 523808， China；*School of Medical Technology，Guangdong Medical University，Dongguan 523808，China

  • Online:2022-11-25 Published:2022-11-25
  • Contact: LIU Yongjun E⁃mail：iuyongjun@gdmu.edu.cn；LIANG Ailing E⁃mail：liangailing@gdmu. edu.cn

Abstract:

Compared with normal cells，tumor cells are more inclined to switch from the Krebs cycle to aerobic glycolysis. PDK4 acts as a bridge in this metabolic transition，and its expression is up ⁃ regulated in most cancer cells. Pyruvate dehydrogenase activity can be regulated by this kinase，which in turn affects various biologi⁃ cal characteristics of tumor cells. In addition，studies on PDK4 and lung cancer development，and drug resistance continue to emerge. This article hopes to provide some ideas for the reversal of tumor resistance，especially NSCLC，by reviewing the research on PDK4 and malignant tumors.

Key words:

PDK4, tumors, drug resistance, NSCLC